Molecular disease presentation in diabetic nephropathy

Nephrology Dialysis Transplantation

Volumn 30, Issue , 2015, Pages iv17-iv25

  Heinzel, Andreas ^a   Mühlberger, Irmgard ^a   Stelzer, Gil ^b   Lancet, Doron ^b   Oberbauer, Rainer ^c   Martin, Maria ^d   Perco, Paul ^a  

^a Emergentec Biodevelopment GmbH   (Austria)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

biological pathways; diabetic nephropathy; functional annotation; molecular disease modeling; omics profiling

Indexed keywords

BIOINFORMATICS; DIABETIC NEPHROPATHY; DISEASE MODEL; GENE ONTOLOGY; GENETIC ASSOCIATION; GENOMICS; HUMAN; METABOLOMICS; MOLECULAR GENETICS; MOLECULAR MODEL; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REVIEW; TRANSCRIPTOMICS; CHRONIC DISEASE; DIABETIC NEPHROPATHIES; DISEASE COURSE; METABOLISM;

BIOLOGICAL MARKER;

BIOMARKERS; CHRONIC DISEASE; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS;

EID: 84939606009     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv267     Document Type: Review

References (57)

1. Ichikawa I, Brenner BM. Glomerular actions of angiotensin II. Am J Med 1984; 76: 43-49
2. Afkarian M, Hirsch IB, Tuttle KR et al. Urinary excretion of RAS, BMP, and WNT pathway components in diabetic kidney disease. Physiol Rep 2014; 2: e12010
3. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
4. Parving HH, Lehnert H, Bröchner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
5. Wu H-Y, Huang J-W, Lin H-J et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ 2013; 347: f6008
6. Freedman BI, Langefeld CD, Lu L et al. Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans. PLoS Genet 2011; 7: e1002150
7. McDonough CW, Palmer ND, Hicks PJ et al. A genome-wide association study for diabetic nephropathy genes in African Americans. Kidney Int 2011; 79: 563-572
8. Brancati FL, Kao WH, Folsom AR et al. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA 2000; 283: 2253-2259
9. Kao WHL, Klag MJ, Meoni LA et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008; 40: 1185-1192
10. Bostrom MA, Lu L, Chou J et al. Candidate genes for non-diabetic ESRD in African Americans: a genome-wide association study using pooled DNA. Hum Genet 2010; 128: 195-204
11. Cooke JN, Bostrom MA, Hicks PJ et al. Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans. Nephrol Dial Transplant 2012; 27: 1505-1511
12. Pezzolesi MG, Poznik GD, Mychaleckyj JC et al. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 2009; 58: 1403-1410
13. Igo RP, Iyengar SK, Nicholas SB et al. Genomewide linkage scan for diabetic renal failure and albuminuria: the FIND study. Am J Nephrol 2011; 33: 381-389
14. Thameem F, Igo RP, Freedman BI et al. A genome-wide search for linkage of estimated glomerular filtration rate (eGFR) in the Family Investigation of Nephropathy and Diabetes (FIND). PLoS One 2013; 8: e81888
15. Sandholm N, McKnight AJ, Salem RM et al. Chromosome 2q31.1 associates with ESRD in women with type 1 diabetes. J Am Soc Nephrol 2013; 24: 1537-1543
16. Wada J, Zhang H, Tsuchiyama Y et al. Gene expression profile in streptozotocin-induced diabetic mice kidneys undergoing glomerulosclerosis. Kidney Int 2001; 59: 1363-1373
17. Cohen CD, Lindenmeyer MT, Eichinger F et al. Improved elucidation of biological processes linked to diabetic nephropathy by single probe-based microarray data analysis. PLoS One 2008; 3: e2937
18. Morrison J, Knoll K, Hessner MJ et al. Effect of high glucose on gene expression in mesangial cells: upregulation of the thiol pathway is an adaptational response. Physiol Genomics 2004; 17: 271-282
19. Cheng DW, Jiang Y, Shalev A et al. An analysis of high glucose and glucosamine-induced gene expression and oxidative stress in renal mesangial cells. Arch Physiol Biochem 2006; 112: 189-218
20. Schmid H, Boucherot A, Yasuda Y et al. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 2006; 55: 2993-3003
21. Woroniecka KI, Park ASD, Mohtat D et al. Transcriptome analysis of human diabetic kidney disease. Diabetes 2011; 60: 2354-2369
22. Tang W, Gao Y, Li Y et al. Gene networks implicated in diabetic kidney disease. Eur Rev Med Pharmacol Sci 2012; 16: 1967-1973
23. Berthier CC, Zhang H, Schin M et al. Enhanced expression of Janus kinasesignal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 2009; 58: 469-477
24. Argyropoulos C, Wang K, McClarty S et al. Urinary microRNA profiling in the nephropathy of type 1 diabetes. PLoS One 2013; 8: e54662
25. Dihazi H, Müller GA, Lindner S et al. Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin Chem 2007; 53: 1636-1645
26. Sharma K, Lee S, Han S et al. Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy. Proteomics 2005; 5: 2648-2655
27. Jin J, Ku YH, Kim Y et al. Differential proteome profiling using iTRAQ in microalbuminuric and normoalbuminuric type 2 diabetic patients. Exp Diabetes Res 2012; 2012: 168602
28. Argilés Á, Siwy J, Duranton F et al. CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS One 2013; 8: e62837
29. Zürbig P, Jerums G, Hovind P et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 2012; 61: 3304-3313
30. Tilton RG, Haidacher SJ, Lejeune WS et al. Diabetes-induced changes in the renal cortical proteome assessed with two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2007; 7: 1729-1742
31. Hwang H-J, Baek Y-M, Kim S-W et al. Differential expression of kidney proteins in streptozotocin-induced diabetic rats in response to hypoglycemic fungal polysaccharides. J Microbiol Biotechnol 2007; 17: 2005-2017
32. Zhang J, Yan L, Chen W et al. Metabonomics research of diabetic nephropathy and type 2 diabetes mellitus based on UPLC-oaTOF-MS system. Anal Chim Acta 2009; 650: 16-22
33. Xia J-F, Liang Q-L, Liang X-P et al. Ultraviolet and tandem mass spectrometry for simultaneous quantification of 21 pivotal metabolites in plasma from patients with diabetic nephropathy. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 1930-1936
34. Han L-D, Xia J-F, Liang Q-L et al. Plasma esterified and non-esterified fatty acids metabolic profiling using gas chromatography-mass spectrometry and its application in the study of diabetic mellitus and diabetic nephropathy. Anal Chim Acta 2011; 689: 85-91
35. Sharma K, Karl B, Mathew AV et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol 2013; 24: 1901-1912
36. Van der Kloet FM, Tempels FWA, Ismail N et al. Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics 2012; 8: 109-119
37. Li M, Wang X, Aa J et al. GC/TOFMS analysis of metabolites in serum and urine reveals metabolic perturbation of TCA cycle in db/db mice involved in diabetic nephropathy. Am J Physiol Renal Physiol 2013; 304: F1317-F1324
38. Hirayama A, Nakashima E, Sugimoto M et al. Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy. Anal Bioanal Chem 2012; 404: 3101-3109
39. Alam-Faruque Y, Dimmer EC, Huntley RP et al. The renal gene ontology annotation initiative. Organogenesis 2010; 6: 71-75
40. RamachandraRao SP, Zhu Y, Ravasi T et al. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 2009; 20: 1765-1775
41. Safran M, Dalah I, Alexander J et al. GeneCards Version 3: the human gene integrator. Database (Oxford) 2010; 2010: baq020
42. Belinky F, Nativ N, Stelzer G et al. PathCards: multi-source consolidation of human biological pathways. Database (Oxford) 2015; 2015: bav006
43. Stelzer G, Dalah I, Stein TI et al. In-silico human genomics with Gene-Cards. Hum Genomics 2011; 5: 709-717
44. Heinzel A, Perco P, Mayer G et al. From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action. Front Cell Dev Biol 2014; 2: 37
45. Vidal M, Cusick ME, Barabási A-L. Interactome networks and human disease. Cell 2011; 144: 986-998
46. Bernthaler A, Mühlberger I, Fechete R et al. A dependency graph approach for the analysis of differential gene expression profiles. Mol Biosyst 2009; 5: 1720-1731
47. Schmitt T, Ogris C, Sonnhammer ELL. FunCoup 3.0: database of genome-wide functional coupling networks. Nucleic Acids Res 2014; 42: D380-D388
48. Bhavnani SK, Eichinger F, Martini S et al. Network analysis of genes regulated in renal diseases: implications for a molecular-based classification. BMC Bioinformatics 2009; 10 (Suppl 9): S3
49. Fechete R, Heinzel A, Perco P et al. Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy. Proteomics Clin Appl 2011; 5: 354-366
50. Sengupta U, Ukil S, Dimitrova N et al. Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications. PLoS One 2009; 4: e8100
51. Ntemka A, Iliadis F, Papanikolaou N et al. Network-centric analysis of genetic predisposition in diabetic nephropathy. Hippokratia 2011; 15: 232-237
52. He L, Sun Y, Takemoto M et al. The glomerular transcriptome and a predicted protein-protein interaction network. J Am Soc Nephrol 2008; 19: 260-268
53. Fechete R, Heinzel A, Söllner J et al. Using information content for expanding human protein coding gene interaction networks. J Comput Sci Syst Biol 2013; 6: 073-082
54. Heinzel A, Mühlberger I, Fechete R et al. Functional molecular units for guiding biomarker panel design. Methods Mol Biol 2014; 1159: 109-133
55. Pena M, Heinzel A, Heinze G et al. A novel panel of biomarkers to predict eGFR decline in type 2 diabetes. PLoS One 2015; 10: e0120995
56. Heinzel A, Fechete R, Mühlberger I et al. Molecular models of the cardiorenal syndrome. Electrophoresis 2013; 34: 1649-1656
57. Heerspink HJL, Grobbee DE, de Zeeuw D. A novel approach for establishing cardiovascular drug efficacy. Nat Rev Drug Discov 2014; 13: 942